Heron Therapeutics(US:HRTX) Globenewswire·2025-11-04 13:00Core Insights - Heron Therapeutics reported financial results for Q3 and the first nine months of 2025, showing significant revenue growth and reaffirming its financial guidance for the year [1][7][3]. Financial Performance - Q3 2025 net revenue reached $38.2 million, a 16.5% increase from $32.8 million in Q3 2024 [7][9]. - Year-to-date revenue for 2025 is $114.3 million, up 10.4% from $103.5 million in the same period of 2024 [10]. - The company reaffirmed its 2025 net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9 million to $13 million [3][7]. Product Performance - ZYNRELEF net revenue grew 49% in Q3 2025 compared to Q3 2024, driven by the launch of the Vial Access Needle and enhanced distributor incentives [7][8]. - APONVIE net revenue surged 173% in Q3 2025 compared to Q3 2024, supported by increased adoption and a dedicated sales team [7][8]. - The Acute Care franchise reported a revenue growth of 67.2% year-over-year in Q3 2025 [8][9]. Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $55.5 million [8]. Corporate Updates - The company launched several new initiatives in Q3 2025 that are positively impacting commercial execution and product demand [2]. - A permanent product-specific J-code for ZYNRELEF was granted, effective October 1, 2025, which is expected to streamline reimbursement processes [8]. Conference Call - Heron will host a conference call and live webcast on November 4, 2025, to discuss these results and updates [11].